Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-25), BioMarin Pharmaceutical's 3-1 Month Momentum % is 9.69%.
The industry rank for BioMarin Pharmaceutical's 3-1 Month Momentum % or its related term are showing as below:
BMRN's 3-1 Month Momentum % is ranked better than 79.63% of 1389
companies
in the Biotechnology industry
Industry Median: -9.61
vs BMRN: 9.69
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
BioMarin Pharmaceutical 3-1 Month Momentum % Related Terms
BMRN vs TECH, CYTK, SMMT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (BMRN) has a 3-1 Month Momentum % of 9.69% as of Aug. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioMarin Pharmaceutical and its competitors. According to the industry distribution chart, BioMarin Pharmaceutical ranks #283 out of 1389 companies in the Biotechnology industry, placing it in the top 20.4%.
Is BioMarin Pharmaceutical's 3-1 Month Momentum % too high?
BioMarin Pharmaceutical's current 3-1 Month Momentum % is 9.69%. Based on the distribution chart, BioMarin Pharmaceutical ranks #283 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's 3-1 Month Momentum % compare to TECH and CYTK?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #283 out of 1389 companies for 3-1 Month Momentum %. This places BioMarin Pharmaceutical in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current 3-1 Month Momentum % is 9.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.53, compared to a current price of $66.12 — trading 20.8% below its estimated fair value. The current 3-1 Month Momentum % is 9.69%. BioMarin Pharmaceutical's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current 3-1 Month Momentum % is 9.69% as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of $66.12 is trading 20.8% below its estimated GF Value™ of $83.53.
GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.
Key valuation signals for BMRN:
3-1 Month Momentum %: 9.69%
GF Value™: $83.53 vs. price of $66.12 (20.8% below fair value)
No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
76GF Score
Get the complete analysis for BMRN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRN has been successfully added to your 
